LABP

Landos Biopharma, Inc. (LABP) | Rumor.io

Landos Biopharma

LABP

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about LABP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 26

Landos Biopharma, Inc. ($LABP) has been acquired by AbbVie ($ABBV) with a cash payout of $20.42 per share.
Shareholders who hold through closing will also receive one Contingent Value Right (CVR) for each share of $LABP, with a potential payout of$11.14 per CVR, contingent on future milestones.
The current premium to the cash offer for $LABP is around$1, with some investors expecting a higher premium of $3, which would bring the total payout to$23.42 per share.

Generated by AI

Sentiment

Of the messages about LABP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +16.58
Bearish	—	—	—	0% -16.58

Mar 25

Big Pharma companies, such as AbbVie, are showing interest in acquiring beaten-up small-cap biopharmas like Landos Biopharma, Inc. ($LABP), which is a positive signal for the rest of the small-cap sector.
Landos Biopharma, Inc. ($LABP) has a promising pipeline, with an ongoing Phase 2 trial for ulcerative colitis and a potential buyout by AbbVie, which could lead to significant returns for investors.
The acquisition of Landos Biopharma, Inc. ($LABP) by AbbVie for up to $212 million could be a catalyst for other beaten-up small-cap biopharmas, such as those in the XBI index, to see a similar increase in value.

Generated by AI

Topics

Of the messages about LABP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Mar 25

AbbVie will acquire Landos Biopharma, Inc. ($LABP) at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate.
The acquisition is expected to strengthen AbbVie's portfolio in inflammatory and autoimmune diseases, with Landos' once-daily oral small molecule offering a novel approach to treating inflammatory bowel disease.
Landos Biopharma's valuation jumps to $212.5 million if the contingent value right triggers, with the company's shares surging 170% after the announcement.

Generated by AI

Community

Of the messages about LABP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	96.67%
Newcomers	—	—	—	3.33%

Regulars· Mar 25

AbbVie is acquiring Landos Biopharma, Inc. (LABP) at a price of $20.42 per share in cash, plus a contingent value right, for a total consideration of approximately $137.5 million.
The acquisition is expected to advance the development of Landos' oral molecule NX-13, aimed at treating ulcerative colitis and Crohn's disease.
The deal strengthens AbbVie's portfolio in inflammatory and autoimmune diseases, with Landos' P2 trial for inflammatory bowel disease expected to be successful.

Newcomers· Mar 25

Perceptive Advisors has a significant stake in LABP, which AbbVie bought for $138 million, and LABP has an ongoing Phase 2 trial for ulcerative colitis.
The acquisition price is $20.42 per share, with a potential additional $75 million based on milestones, and the deal is expected to close in 2Q'24.
AbbVie's acquisition of LABP brings a once-daily oral small molecule with a novel approach to inflammatory bowel disease, and LABP's IPO price was $160 per share in 2021.

Generated by AI

Also Discussed

Investors talking about LABP also mention

#	Name	Attention
1	HARP - Harpoon Therapeutics, Inc.	——
2	ACHL - Achilles Therapeutics plc	——
3	FUSN - Fusion Pharmaceuticals Inc.	——
4	LVTX - LAVA Therapeutics N.V.	——
5	Minerva Surgical Inc.UTRS	0%0
6	Addex Therapeutics LtdADXN	0%0
7	GRCL - Gracell Biotechnologies Inc.	——
8	HeartSciences Inc.HSCS	0%0
9	Verrica Pharmaceuticals Inc.VRCA	0%0
10	AMAM - Ambrx Biopharma Inc.	——